drugset / Trial / NCT00972101

Infusion of Expanded Cord Blood T Cells

NCT00972101

Phase 1 Withdrawn M.D. Anderson Cancer Center
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if treating umbilical cord blood with growth factors before a transplant can help to improve the body's ability to accept the cord blood transplants.

Timeline

Start
2009-09
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic 0.5 mg/kg Intravenous
Subject ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic 1 mg/kg Intravenous
Subject ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic 1.25 mg/kg Intravenous
Subject ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic 1.5 mg/kg Intravenous
Subject ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic 1.75 mg/kg Intravenous
Subject Etoposide Small molecule 60 mg/m2 Intravenous
Subject Fludarabine Small molecule 40 mg/m2 Intravenous
Subject Melphalan Small molecule 140 mg/m2 Intravenous
Subject Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Subject Thiotepa Other / unclassified 10 mg/kg Intravenous
Background G-CSF Unknown 5 ug/kg Subcutaneous
Background Mycophenolate Mofetil Small molecule 15 mg/kg Oral
Background Mycophenolate Mofetil Small molecule 1 g Oral
Background Tacrolimus Small molecule 0.03 mg/kg Intravenous